

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – March 12, 2025 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_94lCoSe9Ty2msgsLMqg2Ww

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 958 2294 2095

Passcode: 65079339

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Haymore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. December 11, 2024 DUR Board Meeting Minutes
- B. December 11, 2024 DUR Board Recommendations Memorandum
- C. January 8, 2025 DUR Board Recommendations Memorandum

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

4. Update on Medication Coverage Authorization Unit – See Appendix B

- A. Pharmacy Help Desk Activity for December 2024
- B. Medication Coverage Activity for December 2024
- C. Pharmacy Help Desk Activity for January 2025
- D. Medication Coverage Activity for January 2025
- E. Pharmacy Help Desk Activity for February 2025
- F. Medication Coverage Activity for February 2025
- G. Correspondence

Items to be presented by Dr. Travers, Dr. Haymore, Chairman:

5. Academic Detailing (AD) Program Update – See Appendix C

- A. AD Program Update

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

6. Narrow Therapeutic Index (NTI) List – See Appendix D

- A. Introduction

- B. SoonerCare NTI List
- C. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

7. Action Item – Vote to Prior Authorize Jubbonti® (Denosumab-bbdz) and Update the Approval Criteria for the Osteoporosis Medications – See Appendix E

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

8. Action Item – Vote to Prior Authorize Aqneursa™ (Levacetylleucine), Lenmeldy™ (Atidarsagene Autotemcel), and Miplyffa™ (Arimoclomol) and Update the Approval Criteria for the Lysosomal Storage Disease Medications – See Appendix F

- A. Market News and Updates
- B. Product Summaries
- C. Cost Comparison: Niemann-Pick Disease Type C (NPC) Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

9. Action Item – Vote to Prior Authorize Yorvipath® (Palopegteriparatide) and Update the Approval Criteria for the Parathyroid Medications – See Appendix G

- A. Market News and Updates
- B. Yorvipath® (Palopegteriparatide) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

10. Action Item – Vote to Prior Authorize Bkempv™ (Eculizumab-aeab), Epysqli® (Eculizumab-aagh), Fabhalta® (Iptacopan), Piasky® (Crovalimab-akkz), and Voydeya™ (Danicopan) and Update the Approval Criteria for the Complement Inhibitors and Miscellaneous Immunomodulatory Agents – See Appendix H

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

11. Action Item – Vote to Prior Authorize Labetalol Hydrochloride 400mg Tablet, Nexiclon™ XR [Clonidine Extended-Release (ER)], and Tryvio™ (Aprocitentan) and Update the Approval Criteria for the Antihypertensive Medications – See Appendix I

- A. Market News and Updates
- B. Tryvio™ (Aprocitentan) Product Summary

- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

12. Action Item – Vote to Prior Authorize Acthar® Gel SelfJect™ (Repository Corticotropin Auto-Injector) and Purified Cortrophin® Gel (Repository Corticotropin Injection) and Update the Approval Criteria for the Adrenocorticotrophic Hormone (ACTH) Products – See Appendix J

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

13. Action Item – Vote to Prior Authorize Diflunisal 500mg Tablet, Dolobid™ (Diflunisal) 250mg and 375mg Tablet, and Indomethacin 50mg Suppository and Update the Approval Criteria for the Systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) – See Appendix K

- A. Market News and Updates
- B. Dolobid™ (Diflunisal) Product Summary
- C. Cost Comparison: Indomethacin Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

14. Action Item – Vote to Prior Authorize Tryngolza™ (Olezarsen) and Update the Approval Criteria for the Antihyperlipidemics – See Appendix L

- A. Market News and Updates
- B. Tryngolza™ (Olezarsen) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

15. Action Item – Vote to Prior Authorize Wyost® (Denosumab-bbdz) – See Appendix M

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

16. Action Item – Vote to Update the Approval Criteria for the Ophthalmic Antibiotic Medications – See Appendix N

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Hughes, Dr. Haymore, Chairman:

17. Action Item – Vote to Prior Authorize Tevimbra® (Tislelizumab-jsgr), Vyloy® (Zolbetuximab-clzb), and Ziihera® (Zanidatamab-hrii) and Update the Approval Criteria for the Gastrointestinal (GI) Cancer Medications – See Appendix O

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Hughes, Dr. Haymore, Chairman:

18. Action Item – Vote to Prior Authorize Fyarro® (Sirolimus Protein-Bound Particles for Injectable Suspension), Niktimvo™ (Axatilimab-csfr), Ojemda™ (Tovorafenib), Tecelra® (Afamitresgene Autoleucel), and Voranigo® (Vorasidenib) and Update the Approval Criteria for the Miscellaneous Cancer Medications – See Appendix P

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

19. Action Item – Annual Review of Short-Acting Beta₂ Agonists (SABAs) – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of SABAs
- C. Prior Authorization of SABAs
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of SABAs

Items to be presented by Dr. Hughes, Dr. Haymore, Chairman:

20. Annual Review of Leukemia and Lymphoma Medications and 30-Day Notice to Prior Authorize Aucatzyl® (Obecabtagene Autoleucel), Danziten™ (Nilotinib), Grafapex™ (Treosulfan), Revuforj® (Revumenib), and Rytelo™ (Imetelstat) – See Appendix R

- A. Current Prior Authorization Criteria
- B. Utilization of Leukemia and Lymphoma Medications
- C. Prior Authorization of Leukemia and Lymphoma Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Leukemia and Lymphoma Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

21. 30-Day Notice to Prior Authorize Kebilidi™ (Eladocagene Exuparvovec-tneq) – See Appendix S

- A. Introduction
- B. Kebilidi™ (Eladocagene Exuparvovec-tneq) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

22. Annual Review of Anti-Migraine Medications and 30-Day Notice to Prior Authorize Symbravo® (Meloxicam/Rizatriptan) – See Appendix T

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Migraine Medications
- C. Prior Authorization of Anti-Migraine Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anti-Migraine Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

23. 30-Day Notice to Prior Authorize Crenessity™ (Crinacerfont) – See Appendix U

- A. Introduction
- B. Crenessity™ (Crinacerfont) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

24. Annual Review of Cholestatic Liver Disease and Bile Acid Disorder Medications and 30-Day Notice to Prior Authorize Ctexli™ (Chenodiol), Iqirvo® (Elafibranor), and Livdelzi® (Seladelpar) – See Appendix V

- A. Current Prior Authorization Criteria
- B. Utilization of Cholestatic Liver Disease and Bile Acid Disorder Medications
- C. Prior Authorization of Cholestatic Liver Disease and Bile Acid Disorder Medications
- D. Market News and Updates
- E. Product Summaries
- F. Cost Comparison: Primary Biliary Cholangitis (PBC) Medications
- G. College of Pharmacy Recommendations
- H. Utilization Details of Cholestatic Liver Disease and Bile Acid Disorder Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

25. Annual Review of Anti-Ulcer Medications and 30-Day Notice to Prior Authorize Pantoprazole in 0.9% Sodium Chloride (NaCl) for Intravenous (IV) Injection – See Appendix W

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Ulcer Medications
- C. Prior Authorization of Anti-Ulcer Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations

F. Utilization Details of Anti-Ulcer Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

26. Annual Review of Heart Failure (HF) Medications and 30-Day Notice to Prior Authorize Entresto® Sprinkle (Sacubitril/Valsartan Oral Pellets) – See Appendix X

- A. Current Prior Authorization Criteria
- B. Utilization of HF Medications
- C. Prior Authorization of HF Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of HF Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

27. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix Y

Items to be presented by Dr. Adams, Dr. Haymore, Chairman:

28. Future Business* (Upcoming Product and Class Reviews)

- A. Granulocyte Colony-Stimulating Factors (G-CSFs) and Stem Cell Mobilizers
- B. Growth Hormone Products and Voxzogo® (Vosoritide)
- C. Hemophilia Medications
- D. Multiple Sclerosis Medications
- E. Muscular Dystrophy Medications

*Future product and class reviews subject to change.

29. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans.